JACKSONVILLE, Fla., Nov. 21, 2017 /PRNewswire/
-- TapImmune Inc. (NASDAQ: TPIV), a leading
clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced its President
and CEO, Peter Hoang, will present at the 29th Annual Piper Jaffray Healthcare Conference held
November 28-29, 2017 in New York, NY.
TapImmune Event Details:
Date: Wednesday, November 29, 2017
Time: 3:50 p.m. (Eastern Time)
Location: Lotte New York Palace Hotel, New York, NY
An audio webcast will be accessible via the News and Events section of the TapImmune website https://tapimmune.com/event/. An archive of the audio will remain available for 90 days following the
presentation.
About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical
studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide- or nucleic acid-based
immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a
patient's killer T-cells and helper T-cells, and to restore or further augment antigen presentation by using proprietary nucleic
acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based
T-cell response and can be given without respect to HLA type. The company's technologies may be used as stand-alone medications
or in combination with other treatment modalities.
For additional information, please call toll free at (904) 862-6490 or visit: tapimmune.com
To receive future press releases via email, please visit: https://tapimmune.com/investors/email-alerts/
Follow us on Twitter @Tapimmune_Inc, or follow
us on Facebook.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995.
Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any
other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters,
are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other
factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and
factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings
which are available through EDGAR at www.sec.gov. The Company
assumes no obligation to update the forward-looking statements.
View original content with multimedia:http://www.prnewswire.com/news-releases/tapimmune-to-present-at-29th-annual-piper-jaffray-healthcare-conference-300559658.html
SOURCE TapImmune Inc.